for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

SINOPHARM HOLDING CO LTD

1099.HK

Latest Trade

26.05HKD

Change

0.10(+0.39%)

Volume

3,556,826

Today's Range

26.00

 - 

26.40

52 Week Range

24.35

 - 

41.00

As of on the Hong Kong Stock Exchange ∙ Minimum 15 minute delay

Latest Developments

Sinopharm Group Posts HY Profit Attributable Of RMB2.98 Bln

Aug 26 (Reuters) - Sinopharm Group Co Ltd <1099.HK>::HY PROFIT ATTRIBUTABLE RMB2.98 BILLION VERSUS RMB2.80 BILLION.HY REVENUE $201.67 BILLION VERSUS RMB163.47 BILLION.

Sinopharm Group Co Says Qtrly Net Profit Attributable RMB 1.14 Billion Versus RMB 891.6 Million

April 26 (Reuters) - Sinopharm Group Co Ltd <1099.HK>::QTRLY NET PROFIT ATTRIBUTABLE RMB1.14 BILLION VERSUS RMB 891.6 MILLION.QTRLY TOTAL OPERATING REVENUE RMB 95.18 BILLION VERSUS RMB 78.94 BILLION.

Sinopharm Group Posts FY Net Profit Of RMB9,404.48 MLN, UP 8.53 PCT

March 25 (Reuters) - SINOPHARM GROUP CO LTD <1099.HK>::FY REVENUE OF RMB344,525.82 MILLION, UP 11.73%.FY NET PROFIT OF RMB9,404.48 MILLION, UP 8.53%.A FINAL DIVIDEND FOR YEAR ENDED 31 DECEMBER 2018 OF RMB0.59 (TAX INCLUSIVE) PER ORDINARY SHARE.

Sinopharm Group's Board Proposes Appointment Of Yu Qingming As An Executive Director

Nov 16 (Reuters) - SINOPHARM GROUP CO LTD <1099.HK>::YU QINGMING APPOINTED AS AN EXECUTIVE DIRECTOR.PROPOSED APPOINTMENT OF YU QINGMING AS EXECUTIVE DIRECTOR IS SUBJECT TO APPROVAL BY SHAREHOLDERS AT GENERAL MEETING OF CO.

Sinopharm Group Co Posts HY Profit Attributable RMB2.68 Bln

Aug 27 (Reuters) - SINOPHARM GROUP CO LTD <1099.HK>::H1 REVENUE RMB 147.49 BILLION VERSUS RMB137.77 BILLION.HY PROFIT ATTRIBUTABLE RMB2.68 BILLION VERSUS RMB2.76 BILLION.

China National Medicines unit to set up medical supply chain management JV with partner

July 12(Reuters) - China National Medicines Corp Ltd <600511.SS>:Says co's Beijing-based unit plans to invest 12 million yuan to set up a Beijing-based medical supply chain management JV with partner, with registered capital of 20 million yuan.Says unit will hold 60 percent stake in the JV.

Sinopharm Group To Buy 60 Pct stake In China National Scientific Instruments And Materials

July 11 (Reuters) - SINOPHARM GROUP CO LTD <1099.HK>::TO BUY 60% STAKE IN CHINA NATIONAL SCIENTIFIC INSTRUMENTS AND MATERIALS CO. LTD HELD BY CHINA NATIONAL PHARMACEUTICAL GROUP CO.DEAL FOR RMB5.11 BILLION.CONSIDERATION TO BE SATISFIED BY ISSUE OF 204.6 MILLION DOMESTIC SHARES BY CO TO CNPGC AT RMB24.97 PER CONSIDERATION SHARE.

China National Medicines to pay A shares div for FY 2017 on June 1

May 24 (Reuters) - China National Medicines Corp Ltd <600511.SS> ::* Says it will pay cash dividend of 0.45 yuan(before tax)/A share for 2017 to shareholders of record on May 31.* The company's shares will be traded ex-right and ex-dividend on June 1 and the dividend will be paid on June 1 .

Sinopharm Group Posts Qtrly Net Profit Attributable RMB842.7 Million

April 27 (Reuters) - SINOPHARM GROUP CO LTD <1099.HK>::QTRLY TOTAL OPERATING REVENUE RMB72.69 BILLION VERSUS RMB68.42 BILLION.QTRLY NET PROFIT ATTRIBUTABLE RMB842.7 MILLION VERSUS RMB1.25 BILLION.

Sinopharm Group Co Expects Q1 Net Profit Attributable Down About 30%

April 10 (Reuters) - SINOPHARM GROUP CO LTD <1099.HK>::EXPECTS Q1 NET PROFIT ATTRIBUTABLE TO RECORD DECLINE OF ABOUT 30%.EXPECTED RESULT DUE TO REVENUE GROWTH SLOWING DOWN DUE TO INFLUENCE OF INDUSTRY POLICIES.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up